Skip to main content
Journal ArticleOPEN ACCESS

Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

  • Parks M
  • Rosebraugh C
New England Journal of Medicine (2010) 362(9) 774-777
DOI: 10.1056/nejmp1001578
240Citations
Citations of this article
134Readers
Mendeley users who have this article in their library.

Abstract

On January 25, the FDA approved liraglutide, a glucagon-like-peptide-1 receptor agonist that can improve glycemic control in adults with type 2 diabetes. Drs. Mary Parks and Curtis Rosebraugh discuss the benefits and potentially serious safety concerns associated with this new therapy.

References Powered by Scopus

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study

Diabetes Care
405Citations
N/AReaders
Get full text

Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules

Journal of Clinical Endocrinology and Metabolism
287Citations
N/AReaders
Get full text
View more at Scopus

Cited by Powered by Scopus

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Cell Metabolism
1078Citations
N/AReaders
Get full text

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

Nature Reviews Endocrinology
1075Citations
N/AReaders
Get full text

Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary

Endocrine Practice
478Citations
N/AReaders
Get full text
View more at Scopus

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Parks, M., & Rosebraugh, C. (2010). Weighing Risks and Benefits of Liraglutide — The FDA’s Review of a New Antidiabetic Therapy. New England Journal of Medicine, 362(9), 774–777. https://doi.org/10.1056/nejmp1001578

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 45

62%

Researcher 17

23%

Professor / Associate Prof. 7

10%

Lecturer / Post doc 4

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 61

69%

Pharmacology, Toxicology and Pharmaceut... 11

12%

Agricultural and Biological Sciences 11

12%

Biochemistry, Genetics and Molecular Bi... 6

7%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 1
References: 4
Social Media
Shares, Likes & Comments: 3

Save time finding and organizing research with Mendeley

Sign up for free